Literature DB >> 21373965

HMGN5: a potential oncogene in gliomas.

Jintao Qu1, Runmin Yan, Juxiang Chen, Tao Xu, Jingxu Zhou, Mei Wang, Chao Chen, Yong Yan, Yicheng Lu.   

Abstract

Gliomas are the most common primary brain tumors in the central nervous system and a leading cause of tumor-related death. High-mobility group nucleosome binding domain 5 (HMGN5/NSBP1), which is highly expressed in breast cancer and in hormone-induced mouse uterine adenocarcinoma, acts as a potential oncogene in gliomas. In this study, the role of HMGN5 in the proliferation of human glioma cells was investigated by lentivirus-mediated RNA interference (RNAi). The decrease in HMGN5 expression in human glioma U251 and U87 cells caused cell cycle arrest in the G1 phase and a delay in cell proliferation, as well as resulting in more apoptosis and an inhibition of clonogenic growth in soft agar in U251 cells; these results suggest that HMGN5 is required for tumorigenesis in vitro. Furthermore, HMGN5 was highly expressed in both high-grade and low-grade glioma tissue samples compared with normal brain tissues. Collectively, our data suggest that HMGN5 may play a critical role in the development of gliomas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21373965     DOI: 10.1007/s11060-011-0558-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  15 in total

Review 1.  HMGN5/NSBP1: a new member of the HMGN protein family that affects chromatin structure and function.

Authors:  Mark Rochman; Cedric Malicet; Michael Bustin
Journal:  Biochim Biophys Acta       Date:  2010 Jan-Feb

Review 2.  The new WHO classification of brain tumours.

Authors:  P Kleihues; P C Burger; B W Scheithauer
Journal:  Brain Pathol       Date:  1993-07       Impact factor: 6.508

Review 3.  Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis.

Authors:  Tao Xu; Juxiang Chen; Yicheng Lu; Johannes Ea Wolff
Journal:  BMC Cancer       Date:  2010-06-02       Impact factor: 4.430

Review 4.  Regulation of chromatin structure and function by HMGN proteins.

Authors:  Yuri Postnikov; Michael Bustin
Journal:  Biochim Biophys Acta       Date:  2009-11-27

5.  Characterization of a human gene encoding nucleosomal binding protein NSBP1.

Authors:  L M King; C A Francomano
Journal:  Genomics       Date:  2001-01-15       Impact factor: 5.736

6.  The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival.

Authors:  Yi-Hong Zhou; Fang Tan; Kenneth R Hess; W K Alfred Yung
Journal:  Clin Cancer Res       Date:  2003-08-15       Impact factor: 12.531

Review 7.  Molecular pathology of malignant gliomas.

Authors:  David N Louis
Journal:  Annu Rev Pathol       Date:  2006       Impact factor: 23.472

Review 8.  Antiangiogenic therapy in malignant gliomas.

Authors:  Andrew D Norden; Jan Drappatz; Patrick Y Wen
Journal:  Curr Opin Oncol       Date:  2008-11       Impact factor: 3.645

9.  Sox11 prevents tumorigenesis of glioma-initiating cells by inducing neuronal differentiation.

Authors:  Takuichiro Hide; Tatsuya Takezaki; Yuka Nakatani; Hideo Nakamura; Jun-ichi Kuratsu; Toru Kondo
Journal:  Cancer Res       Date:  2009-10-06       Impact factor: 12.701

10.  PAX6 suppression of glioma angiogenesis and the expression of vascular endothelial growth factor A.

Authors:  Yi-Hong Zhou; Yuanjie Hu; Debra Mayes; Eric Siegel; Jae G Kim; Marlon S Mathews; Nelson Hsu; Daniel Eskander; Ong Yu; Bruce J Tromberg; Mark E Linskey
Journal:  J Neurooncol       Date:  2009-07-19       Impact factor: 4.130

View more
  12 in total

1.  Evolution of high mobility group nucleosome-binding proteins and its implications for vertebrate chromatin specialization.

Authors:  Rodrigo González-Romero; José M Eirín-López; Juan Ausió
Journal:  Mol Biol Evol       Date:  2014-10-03       Impact factor: 16.240

2.  The high-mobility group nucleosome-binding domain 5 is highly expressed in breast cancer and promotes the proliferation and invasion of breast cancer cells.

Authors:  Mingzhe Weng; Fangbin Song; Jinyu Chen; Junyi Wu; Jun Qin; Tao Jin; Junming Xu
Journal:  Tumour Biol       Date:  2014-10-15

3.  Neonatal exposure to estradiol/bisphenol A alters promoter methylation and expression of Nsbp1 and Hpcal1 genes and transcriptional programs of Dnmt3a/b and Mbd2/4 in the rat prostate gland throughout life.

Authors:  Wan-yee Tang; Lisa M Morey; Yuk Yin Cheung; Lynn Birch; Gail S Prins; Shuk-mei Ho
Journal:  Endocrinology       Date:  2011-11-22       Impact factor: 4.736

4.  Small interfering RNA targeting HMGN5 induces apoptosis via modulation of a mitochondrial pathway and Bcl-2 family proteins in prostate cancer cells.

Authors:  Xiao-Yu Zhang; Zhong-Qiang Guo; Shi-Qi Ji; Min Zhang; Ning Jiang; Xue-Song Li; Li-Qun Zhou
Journal:  Asian J Androl       Date:  2012-04-16       Impact factor: 3.285

5.  Knockdown of HMGN5 suppresses the viability and invasion of human urothelial bladder cancer 5637 cells in vitro and in vivo.

Authors:  Yu Gan; Jing Tan; Jianfu Yang; Yihong Zhou; Yingbo Dai; Leye He; Kun Yao; Yuxin Tang
Journal:  Med Oncol       Date:  2015-03-22       Impact factor: 3.064

Review 6.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

Review 7.  Research advances in HMGN5 and cancer.

Authors:  Zhan Shi; Run Tang; Ding Wu; Xiaoqing Sun
Journal:  Tumour Biol       Date:  2015-12-23

8.  MiR-186 suppresses the growth and metastasis of bladder cancer by targeting NSBP1.

Authors:  Kun Yao; Leye He; Yu Gan; Qing Zeng; Yingbo Dai; Jing Tan
Journal:  Diagn Pathol       Date:  2015-08-20       Impact factor: 2.644

9.  HMGN5 Silencing Suppresses Cell Biological Progression via AKT/MAPK Pathway in Human Glioblastoma Cells.

Authors:  Quanfeng Ma; Xiuyu Wang; Hong Wang; Wen Song; Qiong Wang; Jinhuan Wang
Journal:  Biomed Res Int       Date:  2020-05-21       Impact factor: 3.411

10.  Identification of the Prognostic Signatures of Glioma With Different PTEN Status.

Authors:  Pei Zhang; Xinyi Meng; Liqun Liu; Shengzhen Li; Yang Li; Sakhawat Ali; Shanhu Li; Jichuan Xiong; Xuefeng Liu; Shouwei Li; Qin Xia; Lei Dong
Journal:  Front Oncol       Date:  2021-07-14       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.